Fig. 1: Overview of the belantamab mafodotin Phase II/III clinical development program timeline for key studies in RRMM. | Blood Cancer Journal

Fig. 1: Overview of the belantamab mafodotin Phase II/III clinical development program timeline for key studies in RRMM.

From: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Fig. 1

B belantamab mafodotin, DE dose-escalation, DVd daratumumab, bortezomib and dexamethasone, EMA European Medicines Agency, FDA Food and Drug Administration, LOT line of therapy, Pd pomalidomide and low-dose dexamethasone, PVd pomalidomide, bortezomib and dexamethasone, RP2D recommended Phase II dose, RRMM relapsed refractory multiple myeloma, Vd bortezomib and dexamethasone.

Back to article page